New imaging agent for breast cancer tested – but trial withdrawn

NCT ID NCT05634954

Terminated Diagnosis Sponsor: GE Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study aimed to test a new radioactive imaging agent called [18F]GEH121224 for detecting HER2-positive breast cancer using PET scans. The plan was to enroll 12 women with advanced breast cancer to check safety, radiation exposure, and the best timing for scans. However, the trial was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [18F]GEH121224 (a radioactive imaging agent for PET scans)
What this could lead to: If successful, this imaging agent could help doctors see HER2-positive breast cancer more clearly, guiding treatment decisions.
What could go wrong: This trial was withdrawn before any patients were enrolled, so no data is available. It is very early-stage research, and the agent may not prove safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

The University of Texas MD Anderson Cancer Centre

Houston, Texas, 77030-4008, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.